Charles River Laboratories International, Inc. (CRL) Down 5.7% — Is It Time to Ditch This Stock?
Charles River Laboratories International, Inc. (CRL) came under clear selling pressure in the latest session, with the stock sliding 5.67% to close at $201.12. That move represents a sharp retreat of $12.10 from the prior close of $213.22, marking a noticeable loss of ground in a single day. Trading activity was relatively muted, with about 470,086 shares changing hands, well below the 90‑day average volume of 880,326. This lighter‑than‑usual turnover suggests the latest downside move developed without heavy participation, yet the price still moved decisively lower.
From a broader perspective, the stock remains under pressure when viewed against its recent trading range. CRL now sits meaningfully below its 52‑week high of $228.88, reached on Jan. 13, 2026, giving back a sizable portion of its prior gains as it pulls away from that peak. The current price leaves the shares more than $27 off that high, highlighting how much ground has been lost since investors last saw the stock at its strongest levels over the past year. Within its sector, the negative tone is consistent with softness seen in several peers such as Zoetis Inc. (ZTS), BeOne Medicines AG (ONC), and Natera, Inc. (NTRA), where price action has also been struggling. Overall, the recent slide reinforces a picture of a stock facing headwinds and retreating from its best levels, with near‑term momentum skewed toward the downside.
Why Charles River Laboratories International, Inc. Price is Moving Lower
The recent weakness in Charles River Laboratories International, Inc. shares is occurring against a backdrop of limited fresh catalysts, which can leave stocks vulnerable to selling pressure. With the next major event—the Q4 2025 earnings release and 2026 guidance—still ahead on Feb. 18, 2026, traders appear focused on the fundamental slowdown already visible in the numbers. Quarterly revenue has slipped from $1.03 billion to $1.00 billion, a 2.9% sequential decline, and revenue growth over the trailing period has turned slightly negative at -0.49%. That softness, combined with a negative EPS of -$1.56 and profit margin of -2.04%, raises concerns that profitability is under strain just as investors are demanding clearer evidence of durable earnings power.
These pressures are magnified by elevated expectations. Analysts largely maintain Buy ratings and price targets concentrated around the low-$200s, yet the underlying financial profile looks more muted than the bullish sentiment suggests. Management’s preliminary 2026 outlook calls for at least flat organic revenue growth, which may be interpreted as cautious in a health care and life sciences space where investors typically look for steadier expansion. Recent acquisition announcements—over $500 million in deals expected to be accretive to non-GAAP EPS in 2026 and 2027—also introduce integration risk and near-term execution challenges. In a sector where several peers have struggled with volatility and inconsistent returns, this combination of shrinking recent revenues, negative margins, and a guidance framework that emphasizes cost savings over growth is likely contributing to persistent downside pressure and heightened investor caution.
What is the Charles River Laboratories International, Inc. Rating - Should I Sell?
Weiss Ratings assigns Charles River Laboratories International, Inc. (CRL) a D rating. Current recommendation is Sell. A D rating indicates that, on a risk-adjusted basis, Charles River Laboratories International, Inc. has underperformed peers and offers an unfavorable balance between potential upside and the risks shareholders are taking.
The Weak Growth Index is a central concern. Revenue has slipped by 0.49%, while the company is operating with a negative profit margin of -2.04%. That combination points to a business that is struggling to convert its existing scale into sustainable profitability. The Fair Efficiency Index shows management has some ability to utilize capital, but it is clearly not strong enough to offset deteriorating fundamentals. A deeply negative forward P/E ratio of -136.85 further reflects expectations for weak or volatile earnings ahead, which can translate into additional downside pressure if results disappoint.
On the risk side, the Weak Total Return Index and Weak Volatility Index indicate that shareholders have not been adequately rewarded for the level of price fluctuation they have endured. The Good Solvency Index is one of the few bright spots, suggesting the balance sheet is relatively sound. However, in the context of a D rating, that financial footing has not translated into stable returns or consistent profitability.
Compared with sector peers in Health Care, CRL’s profile is still problematic. Zoetis Inc. (ZTS, D+), BeOne Medicines AG (ONC, D-), and Natera, Inc. (NTRA, D-) all sit in the same broad ratings neighborhood, but CRL’s plain D (Sell) rating highlights a company facing meaningful performance and execution risks that investors should treat with caution.
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. is a contract research and manufacturing organization operating across the global pharmaceuticals, biotechnology and life sciences industry. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company is heavily involved in preclinical stages of drug development, focusing on drug discovery, non-clinical development and safety testing services. Its operations are divided into three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. This structure concentrates the business in earlier, higher-risk phases of the biopharmaceutical pipeline, where delays, cancellations and regulatory scrutiny can directly impact demand for its services.
Through the RMS segment, Charles River produces and sells research models, including purpose-bred rats and mice, and provides related services such as genetically engineered models, insourcing solutions, and research animal diagnostic services. This dependence on animal-based research models exposes the company to ongoing ethical, regulatory and reputational pressures as the life sciences sector gradually shifts toward alternative testing methods. The DSA segment delivers early discovery and in vivo services, as well as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism and pharmacokinetics services, leaving the company closely tied to clients’ success in advancing drug candidates through preclinical safety assessment.
The Manufacturing Solutions segment focuses on in vitro quality control testing for sterile and non-sterile pharmaceuticals and consumer products, along with specialized biologics testing that pharmaceutical and biotechnology companies outsource. Charles River also uses Logica, a platform from Valo Health, to identify small molecule leads, and provides contract vivarium operation services. Strategic collaborations with organizations such as Parker Institute for Cancer Immunotherapy, Children’s Hospital Los Angeles and the Francis Crick Institute support complex offerings like Antibody-Drug Conjugate (ADC) discovery, but also deepen reliance on a limited number of specialized, partnership-driven programs.
Investor Outlook
With Charles River Laboratories International, Inc. (CRL) carrying a D (Sell) Weiss Rating, investors may want to exercise caution and closely monitor whether recent price action confirms ongoing underperformance relative to other Health Care names. Watch for any sustained breaks of recent support levels, shifts in sector sentiment toward research and outsourcing providers, and changes in the key factors driving the D (Sell) assessment, particularly risk and total return. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--